These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35231578)

  • 21. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
    Wang H; Li C; Liu X; Ma M
    Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRBN ligand expansion for hematopoietic prostaglandin D
    Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
    Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Degron Blocking Strategy Towards Improved CRL4
    Bouguenina H; Scarpino A; O'Hanlon JA; Warne J; Wang HZ; Wah Hak LC; Sadok A; McAndrew PC; Stubbs M; Pierrat OA; Hahner T; Cabry MP; Le Bihan YV; Mitsopoulos C; Sialana FJ; Roumeliotis TI; Burke R; van Montfort RLM; Choudhari J; Chopra R; Caldwell JJ; Collins I
    Chembiochem; 2023 Dec; 24(23):e202300351. PubMed ID: 37418539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.
    Desantis J; Bazzacco A; Eleuteri M; Tuci S; Bianconi E; Macchiarulo A; Mercorelli B; Loregian A; Goracci L
    Eur J Med Chem; 2024 Mar; 268():116202. PubMed ID: 38394929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.
    Krieger J; Sorrell FJ; Wegener AA; Leuthner B; Machrouhi-Porcher F; Hecht M; Leibrock EM; Müller JE; Eisert J; Hartung IV; Schlesiger S
    ChemMedChem; 2023 Apr; 18(8):e202200615. PubMed ID: 36749883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform.
    Guo L; Liu J; Nie X; Wang T; Ma ZX; Yin D; Tang W
    Bioorg Med Chem Lett; 2022 Nov; 75():128982. PubMed ID: 36096343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
    Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
    Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
    Mahan SD; Riching KM; Urh M; Daniels DL
    Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E3 ligase ligand optimization of Clinical PROTACs.
    Jiang H; Xiong H; Gu SX; Wang M
    Front Chem; 2023; 11():1098331. PubMed ID: 36733714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
    Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
    Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
    Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
    J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IKZF2 Degradation: It's Time to Take into Account it When Designing Cereblon-Based PROTACs.
    Li M
    Chembiochem; 2024 Aug; 25(16):e202400365. PubMed ID: 38802326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
    Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
    J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains.
    Kaiho-Soma A; Akizuki Y; Igarashi K; Endo A; Shoda T; Kawase Y; Demizu Y; Naito M; Saeki Y; Tanaka K; Ohtake F
    Mol Cell; 2021 Apr; 81(7):1411-1424.e7. PubMed ID: 33567268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
    Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
    J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.